BriaCell Announces Four Clinical Data Presentations at ASCO 2025
BriaCell Therapeutics (Nasdaq: BCTX) has announced four clinical data presentations at the upcoming 2025 ASCO Annual Meeting in Chicago. The presentations include three poster sessions and one publish-only abstract, all focusing on breast cancer treatments.
The presentations will showcase: 1) An update on the phase III pivotal trial of Bria-IMT combined with checkpoint inhibitor versus physician's choice in advanced metastatic breast cancer; 2) Phase I/II survival results of Bria-IMT with checkpoint inhibitor compared to benchmark trials; 3) A trial-in-progress study of Bria-OTS cellular immunotherapy in metastatic recurrent breast cancer; and 4) A publish-only abstract on HLA Matching impact on clinical outcomes in Phase 2 trials.
All poster presentations are scheduled for June 2, 2025, from 9:00 AM to 12:00 PM CDT. The abstracts will be released on May 22, 2025, at 5:00 PM ET, with presentations later available on BriaCell's website.
BriaCell Therapeutics (Nasdaq: BCTX) ha annunciato quattro presentazioni di dati clinici al prossimo 2025 ASCO Annual Meeting che si terrà a Chicago. Le presentazioni comprendono tre sessioni poster e un abstract pubblicato, tutti focalizzati sui trattamenti per il cancro al seno.
Le presentazioni mostreranno: 1) Un aggiornamento sul trial pivotale di fase III di Bria-IMT in combinazione con inibitore del checkpoint rispetto alla scelta del medico nel carcinoma mammario metastatico avanzato; 2) Risultati di sopravvivenza di fase I/II di Bria-IMT con inibitore del checkpoint confrontati con studi di riferimento; 3) Uno studio in corso sul trattamento immunoterapico cellulare Bria-OTS nel carcinoma mammario metastatico ricorrente; e 4) Un abstract pubblicato sull'impatto dell'HLA Matching sugli esiti clinici nelle prove di Fase 2.
Tutte le presentazioni poster sono programmate per il 2 giugno 2025, dalle 9:00 alle 12:00 CDT. Gli abstract saranno pubblicati il 22 maggio 2025 alle 17:00 ET, con le presentazioni successivamente disponibili sul sito web di BriaCell.
BriaCell Therapeutics (Nasdaq: BCTX) ha anunciado cuatro presentaciones de datos clínicos en la próxima Reunión Anual ASCO 2025 en Chicago. Las presentaciones incluyen tres sesiones de póster y un resumen publicado, todos centrados en tratamientos para el cáncer de mama.
Las presentaciones mostrarán: 1) Una actualización del ensayo pivotal de fase III de Bria-IMT combinado con inhibidor de puntos de control frente a la elección del médico en cáncer de mama metastásico avanzado; 2) Resultados de supervivencia de fase I/II de Bria-IMT con inhibidor de puntos de control comparados con ensayos de referencia; 3) Un estudio en curso sobre la inmunoterapia celular Bria-OTS en cáncer de mama metastásico recurrente; y 4) Un resumen publicado sobre el impacto del emparejamiento HLA en los resultados clínicos en ensayos de Fase 2.
Todas las presentaciones en póster están programadas para el 2 de junio de 2025, de 9:00 a 12:00 CDT. Los resúmenes se publicarán el 22 de mayo de 2025 a las 17:00 ET, y las presentaciones estarán disponibles posteriormente en el sitio web de BriaCell.
BriaCell Therapeutics (나스닥: BCTX)는 시카고에서 열리는 2025 ASCO 연례회의에서 네 건의 임상 데이터 발표를 발표했습니다. 발표는 유방암 치료에 중점을 둔 세 개의 포스터 세션과 한 개의 출판 전용 초록으로 구성되어 있습니다.
발표 내용은 다음과 같습니다: 1) 진행성 전이성 유방암에서 Bria-IMT와 체크포인트 억제제 병용의 3상 결정적 임상시험 업데이트; 2) 벤치마크 임상시험과 비교한 Bria-IMT와 체크포인트 억제제의 1/2상 생존 결과; 3) 전이성 재발성 유방암에서 Bria-OTS 세포 면역치료제 진행 중인 임상시험; 4) 2상 임상시험에서 HLA 매칭이 임상 결과에 미치는 영향에 관한 출판 전용 초록.
모든 포스터 발표는 2025년 6월 2일 오전 9시부터 12시(중부일광절약시간)까지 예정되어 있습니다. 초록은 2025년 5월 22일 오후 5시(동부시간)에 공개되며, 발표 내용은 이후 BriaCell 웹사이트에서 확인할 수 있습니다.
BriaCell Therapeutics (Nasdaq : BCTX) a annoncé quatre présentations de données cliniques lors du prochain Congrès annuel ASCO 2025 à Chicago. Les présentations comprennent trois sessions d’affiches et un résumé publié, tous axés sur les traitements du cancer du sein.
Les présentations mettront en avant : 1) Une mise à jour de l’essai pivot de phase III de Bria-IMT combiné à un inhibiteur de points de contrôle versus le choix du médecin dans le cancer du sein métastatique avancé ; 2) Les résultats de survie des phases I/II de Bria-IMT avec inhibiteur de points de contrôle comparés aux essais de référence ; 3) Une étude en cours sur l’immunothérapie cellulaire Bria-OTS dans le cancer du sein métastatique récidivant ; et 4) Un résumé publié sur l’impact de l’appariement HLA sur les résultats cliniques dans les essais de phase 2.
Toutes les présentations affichées sont prévues le 2 juin 2025, de 9h00 à 12h00 CDT. Les résumés seront publiés le 22 mai 2025 à 17h00 ET, avec les présentations ensuite disponibles sur le site web de BriaCell.
BriaCell Therapeutics (Nasdaq: BCTX) hat vier klinische Datenpräsentationen auf dem bevorstehenden 2025 ASCO Annual Meeting in Chicago angekündigt. Die Präsentationen umfassen drei Poster-Sessions und ein nur veröffentlichtes Abstract, alle mit Fokus auf Brustkrebsbehandlungen.
Die Präsentationen zeigen: 1) Ein Update zur phase-III-Schlüsselstudie von Bria-IMT in Kombination mit einem Checkpoint-Inhibitor im Vergleich zur Wahl des Arztes bei fortgeschrittenem metastasiertem Brustkrebs; 2) Überlebensdaten der Phase I/II von Bria-IMT mit Checkpoint-Inhibitor im Vergleich zu Benchmark-Studien; 3) Eine laufende Studie zur Bria-OTS Zellimmuntherapie bei metastasiertem rezidivierendem Brustkrebs; und 4) Ein nur veröffentlichtes Abstract zum Einfluss des HLA-Matchings auf klinische Ergebnisse in Phase-2-Studien.
Alle Posterpräsentationen sind für den 2. Juni 2025 von 9:00 bis 12:00 Uhr CDT geplant. Die Abstracts werden am 22. Mai 2025 um 17:00 Uhr ET veröffentlicht, die Präsentationen sind anschließend auf der Website von BriaCell verfügbar.
- None.
- None.
PHILADELPHIA and VANCOUVER, British Columbia, April 23, 2025 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to announce three clinical data poster presentations and one publish-only abstract at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 30 – June 3 at McCormick Place, Chicago, IL.
The details of the poster presentation sessions and publish-only abstract are listed below.
Abstract Title: Update on phase III pivotal trial of Bria-IMT + CPI vs physician’s choice in advanced metastatic breast cancer (BRIA-ABC)
Session Date and Time: 6/2/2025 9:00 AM-12:00 PM CDT
Abstract Number for Publication: TPS1138
Poster Board Number: 108a
Session Type and Title: Poster Session – Breast Cancer—Metastatic
Abstract Title: Bria-IMT + checkpoint inhibitor: Phase I/II survival results compared to benchmark trials in metastatic breast cancer
Session Date and Time: 6/2/2025 9:00 AM-12:00 PM CDT
Abstract Number for Publication: 1096
Poster Board Number: 75
Session Type and Title: Poster Session – Breast Cancer—Metastatic
Abstract Title: Trial in progress: A study of Bria-OTS cellular immunotherapy in metastatic recurrent breast cancer
Session Date and Time: 6/2/2025 9:00 AM-12:00 PM CDT
Abstract Number for Publication: TPS1136
Poster Board Number: 107a
Session Type and Title: Poster Session – Breast Cancer—Metastatic
Publish-Only Abstract Title: Impact of HLA Matching on Clinical Outcomes in a Phase 2 Trial of Bria-IMT™ Plus Anti PD1 in Advanced Breast Cancer
Abstracts will be released at 5:00 PM (ET) on Thursday, May 22, 2025.
Following the presentations, copies of the presentations will be posted on https://briacell.com/scientific-publications/.
About BriaCell Therapeutics Corp.
BriaCell is a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care. More information is available at https://briacell.com/.
Safe Harbor
This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements, including those about BriaCell presenting four clinical data presentations at the 2025 American Society of Clinical Oncology; and the contents of all such presentations are based on BriaCell’s current expectations and are subject to inherent uncertainties, risks, and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading “Risks and Uncertainties” in the Company's most recent Management’s Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under “Risks and Uncertainties” in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.
Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.
Contact Information
Company Contact:
William V. Williams, MD
President & CEO
1-888-485-6340
info@briacell.com
Investor Relations Contact:
investors@briacell.com
FAQ
What clinical trials will BriaCell (BCTX) present at ASCO 2025?
When and where will BriaCell (BCTX) present its ASCO 2025 data?
What is the focus of BriaCell's (BCTX) Phase III pivotal trial presentation?
How can investors access BriaCell's (BCTX) ASCO 2025 presentations?
